ERD-3111

• Description :

  ERD-3111 (Compound 44) is an orally active PROTAC ERα degrader (DC50: 0.5 nM) . ERD-3111 inhibits tumor growth in the parental MCF-7 xenograft model with wild-type ER and two clinically relevant ESR1 mutated mice model. ERD-3111 can be used in the research of ER+ breast cancer[1].

• CAS Number :

  [2832865-25-3]

• UNSPSC :

  12352005

• Target :

  Estrogen Receptor/ERR; PROTACs

• Type :

  Reference compound

• Related Pathways :

  PROTAC; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/erd-3111.html

• Purity :

  98.72

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  FC(CN1[C@@H](CC2=C([C@H]1C3=C(C=C(C=C3F)N4CCC5(CC4)CCN(C(CN6CC(C=C(C7=C8)C(N(C7=O)C9CCC(NC9=O)=O)=O)=C8C6)=O)CC5)F)C=CC%10=C2C=NN%10)C)F

• Molecular Formula :

  C45H46F4N8O5

• Molecular Weight :

  854.89

• References & Citations :

  [1]Chen Z, et al. Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. J Med Chem. 2023 Aug 30.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported